PSMA PET and MRI in Gynecological Cancers

  • STATUS
    Recruiting
  • End date
    Aug 1, 2023
  • participants needed
    52
  • sponsor
    University of Wisconsin, Madison
Updated on 29 May 2022
cancer
Accepts healthy volunteers

Summary

The goal of this research is to determine the accuracy of PSMA positron emission tomography (PET) and multi-parametric magnetic resonance (MR) imaging to detect the presence of gynecological cancer cells in the body.

Description

The investigators will evaluate a novel second-generation low-molecular-weight prostate specific membrane antigen (PSMA)-based positron emission tomography (PET) agent, 18F-DCFPyL, to determine the presence or absence of cancer, the accurate distribution of cancer and the normal biodistribution of PSMA in the abdomen and pelvis on PET imaging.

PSMA, also known as folate hydrolase 1 and glutamate carboxypeptidase II, is an enzyme associated with prostate cancer but has been also found to be expressed in the tumor neovasculature of many different types of non-prostate cancer tumors. PSMA-based 18F-DCFPyL PET demonstrates very high tumor-to-background ratio when studied in other tumors, including prostate tumors.

MR imaging is a highly sensitive and specific imaging modality that can be used for gynecologic cancers. MR images can be obtained in conjunction with PSMA PET, adding additional anatomic and multi-parametric MRI information without the need for a second imaging appointment.

Details
Condition Gynecologic Cancer
Treatment PSMA-based 18F-DCFPyL PET tracer
Clinical Study IdentifierNCT03302156
SponsorUniversity of Wisconsin, Madison
Last Modified on29 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Women with or without suspected gynecological cancer
No contraindications for MR or PET imaging
Greater than or equal to 18 years of age
Inclusion Criteria for gynecological cancer patients (N=40)
Women with known or suspected gynecological cancer
No contraindications for MR or PET imaging
Greater than or equal to 18 years
Have had or are scheduled to undergo a hysterectomy and/or salpingo-oophorectomy

Exclusion Criteria

Women that are pregnant or breast-feeding
Age <18
Inability to provide informed consent on their own behalf
Severe kidney dysfunction (GFR <30 mL/min/1.73m2)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note